To this end, we analyzed DPYSL5 expression in patient samples using our unique CRPC-NEPC cohort, which includes 135 prostate cancer patient samples, encompassing 55 t-NEPC patient samples. The gene discussed is DPYSL5; the disease is prostate cancer.